12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Faslodex fulvestrant regulatory update

FDA approved a 500 mg dose of intramuscular Faslodex fulvestrant from AstraZeneca to treat hormone receptor-positive metastatic...

Read the full 65 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >